Karyopharm Therapeutics (KPTI) Change in Acquisitions & Divestments (2015 - 2025)

Karyopharm Therapeutics has reported Change in Acquisitions & Divestments for 11 years, with the latest figure at $5.0 million in Q4 2025.

• For the quarter ending Q4 2025, Change in Acquisitions & Divestments fell 69.23% year-over-year to $5.0 million; the trailing twelve-month figure through Dec 2025 stood at $43.4 million (down 71.91% YoY), and the FY2025 full-year result was $43.4 million, down 71.91% from the prior year.
• Change in Acquisitions & Divestments for Q4 2025 stood at $5.0 million, up from $4.8 million in the prior quarter.
• The five-year high for Change in Acquisitions & Divestments was $69.0 million in Q1 2021, with the low at $4.8 million in Q3 2025.
• Historically, Change in Acquisitions & Divestments has averaged $34.0 million across 5 years, with a median of $31.1 million in 2021.
• Annual changes were most pronounced in 2023 — Change in Acquisitions & Divestments soared 113.38% — and 2025, when it plunged 83.01%.
• Karyopharm Therapeutics' Change in Acquisitions & Divestments stood at $30.5 million in 2021, then increased by 4.34% to $31.8 million in 2022, then surged by 36.49% to $43.4 million in 2023, then tumbled by 62.56% to $16.2 million in 2024, then tumbled by 69.23% to $5.0 million in 2025.
• The last three Change in Acquisitions & Divestments figures came in at $5.0 million (Q4 2025), $4.8 million (Q3 2025), and $18.3 million (Q2 2025), per Business Quant data.